Here's Why Astrazeneca (AZN) is a Strong Growth Stock

AstraZeneca (AZN), a leading biopharmaceutical firm, holds a Zacks Rank #3 (Hold) but is highlighted as a strong growth prospect due to its 'A' VGM Score and 'B' Growth Style Score. The company is projected to achieve 11.4% year-over-year earnings growth for the current fiscal year, supported by six recent analyst upgrades for fiscal 2025, which raised the consensus EPS estimate to $4.58 per share, alongside a historical average earnings surprise of +3.5%.

Analysis

AstraZeneca (AZN) presents a nuanced profile, currently holding a Zacks Rank of #3 (Hold) while simultaneously exhibiting strong underlying growth characteristics. The company is projected to deliver 11.4% year-over-year earnings growth for the current fiscal year, a key metric for growth-oriented investors. This positive outlook is further substantiated by upward revisions in analyst sentiment; six analysts have raised their earnings estimates for fiscal 2025 within the last 60 days, pushing the Zacks Consensus Estimate up by $0.08 to $4.58 per share. This trend is complemented by a historical performance of consistently beating expectations, evidenced by an average earnings surprise of +3.5%. The stock's quantitative ratings are also favorable, with a 'B' for its Growth Style Score and an 'A' for its overall VGM (Value, Growth, Momentum) Score, suggesting a well-rounded profile despite the neutral primary rank.

Key Decisions for Investors

• Given the strong growth forecast of 11.4% YoY earnings growth and positive analyst revisions, growth-oriented investors should place AstraZeneca on their watchlist, as the underlying fundamentals appear more robust than the neutral 'Hold' rating suggests.
• Investors should monitor for a potential upgrade in the Zacks Rank from #3 (Hold) to #2 (Buy) or #1 (Strong Buy), which, when combined with the existing 'A' VGM score, would signal a higher-probability entry point.
• Pay close attention to upcoming earnings releases to confirm if the company can meet or exceed the heightened consensus estimate of $4.58 for fiscal 2025 and maintain its track record of positive earnings surprises.
• Despite the strong growth metrics, the 'Hold' rating implies that near-term upside may be limited, suggesting a patient approach is warranted over chasing immediate momentum.